Please assess the completion status of the following clinical trial:

Trial Title: Prospective Trial Comparing Intravesical Chondroitin Sulphate 2% and DMSO in the Treatment of PBS/Interstitial Cystitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Female and male patients from 18-75 years~2. A history of symptoms of bladder pain/discomfort described as suprapubic pain related to bladder filling, accompanied by other symptoms such as daytime and/or nighttime frequency in the absence of infection or other pathology, with or without the typical cystoscopic findings of interstitial cystitis~3. Patients willing and able to complete the necessary questionnaires~Exclusion Criteria:~1. Patients with transitional cell carcinoma of the bladder or other significant malignancy~2. Pregnant women~3. Breastfeading women~4. Patients with significant bacteriuria~5. Patients with hematuria~6. Neurogenic bladder~7. Patients with indwelling catheters~8. Chronic bacterial prostatitis~9. Currently receiving or having received investigational drugs thirty (30) days or less prior to screening~10. Currently receiving or having had prior therapy with intravesical treatment (eg. Uracyst, Cystistat®, heparin or BCG)~11. Receiving therapy for less than three months with antidepressants, antihistaminics, hormonal agonists or antagonists; hence patient not stabilized on therapy. (Stable therapy defined as continuous treatment for at least three months.)~12. IC symptoms relieved by antimicrobials, anticholinergics or antispasmodics~13. Functional Bladder capacity of greater than 400 ml~14. Neurologic disease affecting bladder function; any previous surgery or procedure having affected bladder function~15. Current diagnosis of chemical, tuberculous or radiation cystitis~16. bladder or lower ureteral calculi~17. History of cancer within the last five years other than adequately treated non-melanoma skin cancers~18. Active sexual transmitted disease~19. Current vaginitis~20. Endometriosis~21. Any condition/disease which in the opinion of the investigator could interfere with patient compliance and/ or interfere with the interpretation of the treatment results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Chondroitin sulphate 2% (Type: EXPERIMENTAL): chondoritin sulphate 2% ( Uracyst) for bladder instillation. One bladeer instillation per week during 6 weeks.
- DMSO 50% (Type: ACTIVE_COMPARATOR): DMSO 50% in saline for bladder instillation. One bladder instillation per week during 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).